Among various approved anti-diabetic medications, metformin in particular could plausibly offer the most pronounced endometrial cancer risk-reducing effect as it has been shown to not only increase insulin sensitivity, thus reversing insulin resistance and lowering fasting insulin levels, but also inhibit endometrial proliferation [9, 128]. This evidence concerns the gene INS and endometrial cancer.